Edward M. Md Kaye Cytokinetics Inc (CYTK) insider trading activity

Edward M. Md Kaye is Director of CYTOKINETICS INC. Currently has a direct ownership of 25,637 shares of CYTK, which is worth approximately $1.18 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 255 shares (Common Stock) at a price of $48.93 per share, resulting in proceeds of $12,477. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.6K

1.0% 3M change

32.72% 12M change

Total Value Held $1.18 Million

Edward M. MD Kaye Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	BUY Grant, award, or other acquisition	$12,477 $48.93 p/Share	255 Added 0.98%	25,637 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	$12,466 $52.6 p/Share	237 Added 0.93%	25,382 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	228 Added 0.9%	25,145 Common Stock
May 15 2024	BUY Grant, award, or other acquisition	-	5,600 Added 18.35%	24,917 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	$12,449 $84.12 p/Share	148 Added 0.76%	19,317 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	$12,490 $27.88 p/Share	448 Added 2.28%	19,169 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	$12,476 $33.36 p/Share	374 Added 1.96%	18,721 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	5,000 Added 21.42%	18,347 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	$11,237 $37.71 p/Share	298 Added 2.18%	13,347 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	$11,220 $44.35 p/Share	253 Added 1.9%	13,049 Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	$11,244 $51.11 p/Share	220 Added 1.69%	12,796 Common Stock
Aug 05 2022	SELL Open market or private sale	$571,400 $50.0 p/Share	11,428 Reduced 47.61%	12,576 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$99,995 $8.75 p/Share	11,428 Added 32.25%	24,004 Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	$11,234 $41.0 p/Share	274 Added 2.13%	12,576 Common Stock
May 10 2022	BUY Grant, award, or other acquisition	-	5,000 Added 28.9%	12,302 Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	$11,245 $38.38 p/Share	293 Added 3.86%	7,302 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	$11,224 $46.0 p/Share	244 Added 3.36%	7,009 Common Stock
Dec 23 2021	SELL Open market or private sale	$675,000 $45.0 p/Share	15,000 Reduced 68.92%	6,765 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$114,150 $7.61 p/Share	15,000 Added 40.8%	21,765 Common Stock
Oct 01 2021	BUY Grant, award, or other acquisition	$11,242 $36.74 p/Share	306 Added 4.33%	6,765 Common Stock
Jul 07 2021	BUY Grant, award, or other acquisition	$1,246 $19.77 p/Share	63 Added 0.97%	6,459 Common Stock
Jul 01 2021	BUY Grant, award, or other acquisition	$9,986 $20.98 p/Share	476 Added 6.93%	6,396 Common Stock
May 12 2021	BUY Grant, award, or other acquisition	-	5,000 Added 45.79%	5,920 Common Stock
Apr 01 2021	BUY Grant, award, or other acquisition	$9,996 $24.44 p/Share	409 Added 30.78%	920 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	$9,995 $19.56 p/Share	511 Added 50.0%	511 Common Stock

Also insider at

STOK

Stoke Therapeutics, Inc. Healthcare

CEO

RNA

Avidity Biosciences, Inc. Healthcare

Director

EMM

Edward M. Md Kaye

Director

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account